Madrigal Pharmaceuticals, Inc. MDGL

MDGL Company Overview

Madrigal Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for metabolic and liver diseases. The company operates within the biotechnology and pharmaceuticals industries, with a primary emphasis on nonalcoholic steatohepatitis, now more commonly referred to as metabolic dysfunction–associated steatohepatitis (MASH). Madrigal’s core value proposition centers on addressing diseases with high unmet medical need through targeted, mechanism-driven therapies.

The company’s principal product and revenue driver is Rezdiffra (resmetirom), a thyroid hormone receptor‑β selective agonist approved by the U.S. Food and Drug Administration in March 2024 for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. Madrigal evolved from a clinical-stage biotechnology company into a commercial-stage organization following this approval, marking a significant inflection point in its corporate history. Public sources consistently describe Madrigal as having a highly focused pipeline rather than a diversified portfolio.